ICOS Corporation

ICOS Corporation is developing proprietary biopharmaceuticals and small molecule pharmaceuticals for thetreatment of inflammatory diseases and other serious medical conditions. The Company's fundamental strategy is to identify and develop a significant number of potential product candidates into breakthrough products with high commercial potential. By understanding the underlying biochemical and physiological mechanisms and identifying the cellular and molecular entities involved in the disease process, ICOS is developing biopharmaceutical products that address important opportunities in the treatment of chronic and acute diseases that have inflammatory components as well as certain cardiovascular diseases and cancer. Through this strategy, the Company believes it will be able to develop novel therapeutics that are more selective and efficacious than current therapeutics.

Contact Details: 22021 20th Avenue SouthEast Bothell Washington 98021 United States of America Tel: 425 485 1900 Fax: 425 489 0356 Email: WWW: www.icos.com/

Loading...

Recent Publications by ICOS Corporation:
Disruption of nNOS-PSD95 protein-protein interaction inhibits acute thermal hyperalgesia and chronic mechanical allodynia in rodents. BACKGROUND AND PURPOSE: Post-synaptic density protein 95 (PSD95) contains...	8th September, 2009	ICOS Corporation, Bothell, WA, USA.	Br J Pharmacol. 2009 Sep;158(2):494-506. DOI Direct Link
Regulation of fibrosis by the immune system. Inflammation and fibrosis are two inter-related conditions with many...	30th April, 2009	ICOS Corporation, Bothell, Washington, USA.	Adv Immunol. 2006;89:245-88. DOI Direct Link
Novel tools for functional analysis of CD11c: activation-specific, activation-independent, and activating antibodies. Functions and binding properties of four CD11c-specific mAbs are described...	1st April, 2008	ICOS Corporation,	J Immunoassay Immunochem. 2008;29(1):42-57. DOI Direct Link
CD11c/CD18: novel ligands and a role in delayed-type hypersensitivity. CD11c, a member of the leukointegrin family, is expressed prominently on...	18th September, 2007	ICOS Corporation, 22021 20th Ave., S.E., Bothell, WA 98021, USA.	J Leukoc Biol. 2007 Jun;81(6):1395-403. Epub 2007 Mar 27. DOI Direct Link
Enhancement of Natural Killer cell cytotoxicity by a CD18 integrin-activating antibody. Natural Killer (NK) cells kill certain tumor cells and virus infected...	21st July, 2007	ICOS Corporation, 22021 20th Avenue SE, Bothell, WA 98021, USA.	Biochem Biophys Res Commun. 2007 Jul 6;358(3):938-41. Epub 2007 May 14. DOI Direct Link
→View more ICOS Corporation research publications.

Press Releases on ICOS Corporation:
Oncothyreon appoints Scott Peterson as Vice President of Research and Development	15th June, 2009	Oncothyreon Inc.	SEATTLE, June 15 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the "Company") today announced the appointment of Scott Peterson, Ph.D., as Vice President, Research and

BioNews Results for ICOS Corporation:
An Ode to Schering-Plough	Motley Fool via MSN Money:  Nov 4 2009 11:52PM Matching: icos
An Ode to Schering-Plough	Motley Fool:  Nov 4 2009 9:45PM Matching: icos
Gilead Sciences, GlaxoSmithKline Reveals Phase IV Combination Study Of Pulmonary Hypertension Drugs - Update	RTTNews.com:  Nov 2 2009 6:45PM Matching: icos
Red Flags in Biotech	Cafepharma:  Oct 23 2009 6:44PM Matching: icos
Red Flags in Biotech	Corante:  Oct 23 2009 2:15AM Matching: icos
Promote your company here: BioNewsCast - Press Release Distribution	→View more ICOS Corporation news.

ICOS Corporation Clinical Trials:
Safety and Efficacy of Sitaxsentan in the Treatment of Pulmonary Arterial Hypertension

ICOS Corporation Patents:
US Patent No.	Title
6790947	Polynucleotides encoding macrophage derived chemokine
6911542	Pyrazino[1',2':1,6]pyrido[3,4b]indole derivatives
6924284	PARP inhibitors
6943166	Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
6949535	Inhibitors of human phosphatidyl-inositol 3-kinase delta
→View more ICOS Corporation patents.

ICOS Corporation (ICOS) Financial information Links from Barchart
ICOS Quote from from Barchart.com
ICOS Chart from from Barchart.com
ICOS Profile from from Barchart.com
ICOS Opinion from from Barchart.com
→View more ICOS Corporation finance information.

BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 23 individuals from ICOS Corporation using this service.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 772 times since April 2007, the link to the organisation's website has been followed 147 times

Recent Search Terms used to find this page: icos corporation bothell wa | icos corporation | ICOS Corporation Bothell Wash | ICOs corporation telephone | icos corporation bothell wa | icos corporation bothell wa | icos corporation bothell wa | ICOS Corp. Bothell WA . | icos corporation bothell wa | icos corporation | .

Search for more companies in Bothell

Search for more companies in Washington

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for ICOS Corporation